Abstract
The dextrorotatory morphinan dextromethorphan (DM), a clinically tested antagonist of the N-methyl-d-aspartate (NMDA) receptor-channel complex, was tested in an in vivo model of acute transient focal cerebral ischemia. Rabbits were randomly assigned to pretreatment with a 20 mg/kg i.v. bolus followed by 10 mg/kg/h of 0.4% DM in normal saline (NS), or with an equivalent volume of NS alone. They then underwent 1 h occlusion of the left internal carotid artery and anterior cerebral artery followed by 4 h of reperfusion. DM-treated animals showed a significant decrease in the percentage of severe neocortical ischemic neuronal damage (10.5%), as compared to NS-treated animals (49.6%).
Original language | English (US) |
---|---|
Pages (from-to) | 375-379 |
Number of pages | 5 |
Journal | Brain Research |
Volume | 440 |
Issue number | 2 |
DOIs | |
State | Published - Feb 9 1988 |
Externally published | Yes |
Keywords
- Dextromethorphan
- Ischemia
- N-methyl-d-aspartic acid (NMDA)
- Neocortex
- Striatum
ASJC Scopus subject areas
- General Neuroscience
- Molecular Biology
- Clinical Neurology
- Developmental Biology